# ChomiX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chomix

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.chomixbiotech.com
- Total disclosed funding: $1.5M
- Latest round: Angel (Jul 5, 2021)
- Investors on record: 1

## About

Based in Nanjing, China, and established in 2021, ChomiX is an biopharmaceutical company that focuses on R&D of proteomics used in the fields of drug target identification, protein target discovery and covalent drug lead compound screening. The company integrated chemical, biological and medical research. As for the team, the chief scientist of the company is Prof. Chu Wang from Peking University, the scientific advisory team is led by academician Mr. Zijian Guo from Nanjing University, and seven Chinese scholars in the field of chemical biology are gathered, focusing on the field of chemical proteomics.

The company's business can be divided into chemical proteomics technical service platform, protein marking technology service platform, kit products, and drug compound screening. The chemical proteomics technical service platform can solve post-translational modification of protein analysis, drug target identification, and metabolite binding protein analysis, and etc. The protein marking technology service platform can directly label non-modified antibodies. The kits includes Amino acid residue-specific labeled probe, post-translational modification specific labeled probe bifunctional corsslinking agent, non-natural chemical reporter probe, and small molecule fluorescent probe.

## Funding rounds

- Angel, Jul 5, 2021, $1.5M — InnoMed Capital

## Investors

- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Angel